Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis

Table 1 Characteristics of included studies. Abbreviations: NSCLC (non-small lung cancer); S-NSCLC (squamous non-small lung cancer); NS-NSCLC (non-squamous non-small lung cancer); RCC (renal cell cancer); H&N (head & neck); NR (not reported); Q (every); W (weeks)

	Study Name	Drug	Phase	Malignancy	First line	Arm 1	Arm 2	Arm 3	Patient’ number	Age median	Age range	Age mean	n (%) < 65 y	n (%) ≥ 65 y
Rittmeyer 2016 [33]	OAK	Atezolizumab	3	NSCLC	N	Atezolizumab 1200 mg Q 3 W	Docetaxel 75 mg/m² Q 3 W		850	64	33–85	63	453 (53)	397 (47)
Fehrenbacher 2016 [26, 34]	POPLAR	Atezolizumab	2	NSCLC	N	Atezolizumab 1200 mg Q 3 W	Docetaxel 75 mg/m² Q 3 W		287	62	36–84	61.5	174 (61)	113 (39)
Brahmer 2015 [5]	Checkmate-017	Nivolumab	3	S-NSCLC	N	Nivolumab 3 mg/kg Q 2 W	Docetaxel 75 mg/m² Q 3 W		272	63	39–85	63	152 (56)	120 (44)
Borghaei 2015 [6]	Checkmate-057	Nivolumab	3	NS-NSCLC	N	Nivolumab 3 mg/kg Q 2 W	Docetaxel 75 mg/m² Q 3 W		582	62	21–85	NR	339 (58)	243 (42)
Motzer 2015 [4]	Checkmate-025	Nivolumab	3	RCC	N	Nivolumab 3 mg/kg Q 2 W	Everolimus 10 mg daily		821	62	18–88	61.3	497 (61)	324 (39)
Robert 01–2015 [29]	Checkmate-066	Nivolumab	3	Melanoma	Y	Nivolumab 3 mg/kg Q 2 W	Dacarbazine 1000 mg/m² Q 3 W		418	65	18–87	62.7	200 (48)	218 (52)
Ferris 2016 [2]	Checkmate-141	Nivolumab	3	H&N	N	Nivolumab 3 mg/kg Q 2 W	Chemotherapy		361	60	28–83	59.1	248 (69)	113 (31)
Herbst 2016 [8]	Keynote-010	Pembrolizumab	2/3	NSCLC	N	Pembrolizmab 2 mg/kg Q 3 W	Pembrolizumab 10 mg/kg Q 3 W	Docetaxel 75 mg/m² Q 3 W	1033	NR	NR	62	604 (58)	429 (42)
Robert 06–2015 [9]	Keynote-006	Pembrolizumab	3	Melanoma	N	Pembrolizumab 10 mg/kg Q 2 W	Pembrolizumab 10 mg/kg Q 3 W	Ipilimumab 3 mg/kg Q 3 W	834	NR	NR	60.3	467 (56)	367 (44)